

Elke H J Krekels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/481352/publications.pdf>

Version: 2024-02-01

58
papers

1,461
citations

304743

22
h-index

330143

37
g-index

60
all docs

60
docs citations

60
times ranked

1627
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 89-98.	1.9	0
2	Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 99-109.	2.0	3
3	An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 99-113.	3.3	10
4	Effect of Different Exercise Training Modalities on Fasting Levels of Oxylipins and Endocannabinoids in Middle-Aged Sedentary Adults: A Randomized Controlled Trial. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2022, 32, 275-284.	2.1	2
5	Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker. <i>AAPS Journal</i> , 2022, 24, 38.	4.4	6
6	Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. <i>Obesity</i> , 2022, 30, 50-61.	3.0	21
7	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2217-2226.	3.0	4
8	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1167-1175.	3.5	9
9	The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 140-149.	4.7	14
10	Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. <i>Pediatric Research</i> , 2021, 90, 1201-1206.	2.3	3
11	Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. <i>AAPS Journal</i> , 2021, 23, 65.	4.4	6
12	Towards Evidence-Based Weaning: a Mechanism-Based Pharmacometric Model to Characterize Iatrogenic Withdrawal Syndrome in Critically Ill Children. <i>AAPS Journal</i> , 2021, 23, 71.	4.4	3
13	Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 1-34.	0.6	3
14	Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. <i>Pharmaceutical Research</i> , 2021, 38, 1711-1720.	3.5	0
15	Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 786-795.	4.7	25
16	Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans. <i>British Journal of Pharmacology</i> , 2020, 177, 5518-5533.	5.4	10
17	Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. <i>Pediatric Critical Care Medicine</i> , 2020, 21, e707-e715.	0.5	7
18	Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1231-1236.	2.0	3

#	ARTICLE	IF	CITATIONS
19	Quantification of Natural Growth of Two Strains of <i>Mycobacterium Marinum</i> for Translational Antituberculosis Drug Development. <i>Clinical and Translational Science</i> , 2020, 13, 1060-1064.	3.1	5
20	Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> , 2020, 80, 671-695.	10.9	80
21	The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1291-1301.	3.5	10
22	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. <i>AAPS Journal</i> , 2019, 21, 81.	4.4	8
23	Dose-Dependency of the pharmacokinetics of an intravenous [¹⁴ C]midazolam microdose in children. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2332-2340.	2.4	15
24	Supervised Multidimensional Item Response Theory Modeling of Pediatric Iatrogenic Withdrawal Symptoms. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 904-912.	2.5	4
25	Children Are Not Small Adults, but Can We Treat Them As Such?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 34-38.	2.5	16
26	Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae. <i>Scientific Reports</i> , 2019, 9, 2149.	3.3	22
27	Mechanistic and Quantitative Understanding of Pharmacokinetics in Zebrafish Larvae through Nanoscale Blood Sampling and Metabolite Modeling of Paracetamol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 15-24.	2.5	24
28	Enteral Acetaminophen Bioavailability in Pediatric Intensive Care Patients Determined With an Oral Microtracer and Pharmacokinetic Modeling to Optimize Dosing. <i>Critical Care Medicine</i> , 2019, 47, e975-e983.	0.9	11
29	Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools. <i>AAPS Journal</i> , 2019, 21, 11.	4.4	2
30	The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models. <i>Clinical Pharmacokinetics</i> , 2019, 58, 131-138.	3.5	8
31	Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 231-255.	1.8	1
32	Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 175-185.	2.5	19
33	Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 417-428.	3.3	14
34	Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models. <i>AAPS Journal</i> , 2018, 20, 5.	4.4	8
35	Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 358-368.	2.4	25
36	Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory. <i>Pharmaceutical Research</i> , 2018, 35, 209.	3.5	8

#	ARTICLE	IF	CITATIONS
37	Firstâ€Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 374-383.	2.5	23
38	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. Pharmaceutical Research, 2018, 35, 182.	3.5	24
39	Outsideâ€In Systems Pharmacology Combines Innovative Computational Methods With Highâ€Throughput Whole Vertebrate Studies. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 285-287.	2.5	13
40	Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics, 2017, 13, 9.	3.0	64
41	Evidence-based drug treatment for special patient populations through model-based approaches. European Journal of Pharmaceutical Sciences, 2017, 109, S22-S26.	4.0	37
42	Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 543-551.	2.5	19
43	Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
44	Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?. Clinical Pharmacokinetics, 2017, 56, 273-285.	3.5	86
45	Pain and distress caused by endotracheal suctioning in neonates is better quantified by behavioural than physiological items: a comparison based on item response theory modelling. Pain, 2016, 157, 1611-1617.	4.2	38
46	Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude. Zebrafish, 2016, 13, 504-510.	1.1	66
47	Systems pharmacology of hepatic metabolism in zebrafish larvae. Drug Discovery Today: Disease Models, 2016, 22, 27-34.	1.2	31
48	Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Review of Clinical Pharmacology, 2016, 9, 1235-1244.	3.1	23
49	Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial. Clinical Pharmacokinetics, 2016, 55, 1079-1090.	3.5	27
50	Population pharmacokinetics of edoxaban in patients with symptomatic deepâ€vein thrombosis and/or pulmonary embolismâ€the Hokusaiâ€VTE phase 3 study. British Journal of Clinical Pharmacology, 2015, 80, 1374-1387.	2.4	18
51	Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. European Journal of Clinical Pharmacology, 2015, 71, 1075-1082.	1.9	30
52	Pediatric pharmacology: current efforts and future goals to improve clinical practice. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1679-1682.	3.3	6
53	Evidence-Based Morphine Dosing for Postoperative Neonates and Infants. Clinical Pharmacokinetics, 2014, 53, 553-563.	3.5	70
54	Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. Clinical Pharmacokinetics, 2011, 50, 51-63.	3.5	51

#	ARTICLE	IF	CITATIONS
55	Advances in paediatric pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1-8.	3.3	39
56	Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models. Pharmaceutical Research, 2011, 28, 797-811.	3.5	56
57	The role of population PKâ€“PD modelling in paediatric clinical research. European Journal of Clinical Pharmacology, 2011, 67, 5-16.	1.9	175
58	Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years. Clinical Pharmacokinetics, 2009, 48, 371-385.	3.5	129